Restricted Research - Award List, Note/Discussion Page

Fiscal Year: 2018

1662  University of Houston  (75480)

Principal Investigator: Ruiwen Zhang

Total Amount of Contract, Award, or Gift (Annual before 2011): $ 2,907,835

Exceeds $250,000 (Is it flagged?): Yes

Start and End Dates: 9/4/17 - 8/31/22

Restricted Research: YES

Academic Discipline: PHARMACOLOGICAL & PHARMACEUTIC

Department, Center, School, or Institute: DEAN, PHARMACY

Title of Contract, Award, or Gift: NOVEL NFAT1-MDM2 INHIBITOR FOR BREAST CANCER THERAPY

Name of Granting or Contracting Agency/Entity: National Cancer Institute
CFDA Link: HHS
93.395

Program Title: CHANGE OF GRANTEE INSTITUTION PROPOSAL - PHS398
CFDA Linked: Cancer Treatment Research

Note:

1.1.1 - Grant with a long-term objective to develop a novel dual-targeting therapeutic strategy (MDM2 and NFAT1) for the treatment of advanced breast cancer.

Discussion: No discussion notes

 

Close Window